STRATA Skin Sciences Highlights Meta-Analysis Confirming Efficacy of 308 nm Excimer Laser for Plaque Psoriasis Treatment

STRATA Skin Sciences announces a meta-analysis confirming 308 nm Excimer laser's effectiveness in treating plaque psoriasis.

Quiver AI Summary

STRATA Skin Sciences, Inc. announced the positive findings of a systematic review and meta-analysis published in the Journal of Drugs in Dermatology, highlighting the effectiveness of 308 nm Excimer laser therapy for treating plaque psoriasis. Conducted by researchers from Georgetown University and MedStar Washington Hospital Center, the analysis demonstrated significant improvements in the Psoriasis Area and Severity Index (PASI) scores among patients treated with the laser, showing reductions of 56% to 85% after 10 to 14 sessions. The study emphasized the benefits of MED-guided dosing, which allows for precise delivery of high-fluence UVB light to target psoriasis plaques while protecting surrounding skin, enhancing treatment outcomes. STRATA continues its commitment to developing and advancing innovative dermatological therapies to improve patient care for chronic skin conditions.

Potential Positives

Publication of a systematic review and meta-analysis in the Journal of Drugs in Dermatology confirms the clinical efficacy of the 308 nm Excimer laser for treating plaque psoriasis.
Significant reductions in PASI scores were reported across multiple studies, demonstrating substantial clinical improvements for patients treated with this technology.
STRATA's XTRAC® technology models enable efficient delivery of optimized targeted doses, supporting short treatment times and favorable practice economics.
The study underscores STRATA's commitment to advancing evidence-based dermatologic therapies, enhancing its reputation within the medical community.

Potential Negatives

The press release emphasizes the efficacy of the 308 nm Excimer laser, but it does not disclose any potential side effects or risks associated with the treatment, which may raise concerns among patients and healthcare providers.
While the publication showcases several positive PASI improvements, it relies on previously published studies, which could limit the perceived credibility of the results and raise questions about the novelty of the findings.
The press release includes a "Safe Harbor" statement indicating inherent uncertainties in the company's future statements, which may lead to investor apprehension regarding the company's stability and future performance.

FAQ

What is the 308 nm Excimer laser's efficacy in treating plaque psoriasis?

The 308 nm Excimer laser has demonstrated significant improvement in plaque psoriasis, as confirmed by a recent systematic review and meta-analysis.

What were the key findings from the February 2026 meta-analysis?

The meta-analysis found substantial reductions in PASI scores across multiple studies, highlighting the efficacy of the 308 nm Excimer laser therapy.

How does MED-guided dosing work in excimer laser therapy?

MED-guided dosing customizes the UVB fluence based on individual lowest fluence levels producing visible erythema, enhancing treatment effectiveness.

How many treatments are typically needed for effective results?

Patients generally achieve significant PASI reductions within 10 to 14 treatments over approximately 5 to 7 weeks.

What technology does STRATA Skin Sciences offer for psoriasis treatment?

STRATA Skin Sciences offers high-power XTRAC® technology, enabling efficient delivery of targeted doses for effective psoriasis treatment.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$SSKN Insider Trading Activity

$SSKN insiders have traded $SSKN stock on the open market 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $SSKN stock by insiders over the last 6 months:

SAMUEL RUBINSTEIN has made 2 purchases buying 5,000 shares for an estimated $7,028 and 3 sales selling 14,094 shares for an estimated $18,803.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$SSKN Revenue

$SSKN had revenues of $6.9M in Q3 2025. This is a decrease of -21.23% from the same period in the prior year.

You can track SSKN financials on Quiver Quantitative's SSKN stock page.

$SSKN Hedge Fund Activity

We have seen 4 institutional investors add shares of $SSKN stock to their portfolio, and 9 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

RENAISSANCE TECHNOLOGIES LLC removed 37,700 shares (-37.1%) from their portfolio in Q4 2025, for an estimated $47,502
AZZAD ASSET MANAGEMENT INC /ADV removed 21,800 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $27,468
MGO ONE SEVEN LLC removed 17,142 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $21,598
APOLLON WEALTH MANAGEMENT, LLC added 15,105 shares (+inf%) to their portfolio in Q4 2025, for an estimated $19,032
TOWER RESEARCH CAPITAL LLC (TRC) removed 12,912 shares (-87.6%) from their portfolio in Q3 2025, for an estimated $26,598
SUSQUEHANNA INTERNATIONAL GROUP, LLP added 12,426 shares (+inf%) to their portfolio in Q3 2025, for an estimated $25,597
VANGUARD GROUP INC removed 7,170 shares (-30.5%) from their portfolio in Q4 2025, for an estimated $9,034

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

HORSHAM, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today highlights findings from a February 2026 systematic review and meta-analysis confirming the clinical efficacy of 308 nm Excimer laser in plaque psoriasis. Published in the Journal of Drugs in Dermatology by investigators from Georgetown University School of Medicine and the Department of Dermatology at MedStar Washington Hospital Center, the analysis evaluated clinical trials assessing the efficacy of the 308 nm excimer laser for plaque psoriasis. Across the included studies, patients were treated twice weekly for a minimum of 10 sessions , with outcomes measured using the Psoriasis Area and Severity Index (PASI). The study by Gratz, Ben, et al., titled, "Excimer Laser for Plaque Psoriasis: A Systematic Review and Meta-analysis" was published in the Journal of Drugs in Dermatology ( JDD 25.2 (2026): e36-e37.).

“This meta-analysis reinforces what dermatologists have observed clinically — that properly calibrated, MED-guided Excimer Laser therapy provides effective, targeted treatment for plaque psoriasis,” said Dr. Dolev Rafaeli, STRATA Skin Sciences Chief Executive Officer. “Enabling the delivery of high-fluence 308nm UVB precisely to affected plaques while sparing surrounding healthy skin represents a meaningful therapeutic advantage.”

Significant PASI Improvements Across Studies

The meta-analysis demonstrated substantial and statistically significant reductions in PASI scores through review of previously published studies, including:

Tang et al. (n=32): PASI improved from 11.47 to 5.08 (~56% reduction)
He et al. (n=40): PASI improved from 14.73 to 2.42 (~84% reduction)
Gerber et al. (n=100): PASI improved from 13.70 to 2.10 (~85% reduction)
Dong et al. (n=20): PASI improved from 12.02 to 4.09 (~66% reduction)

Patients typically achieved these outcomes within 10–14 treatments over approximately 5–7 weeks , underscoring the efficiency of targeted excimer laser protocols.

MED-Guided Dosing and Targeted Fluence Delivery

A key focus of the publication was the role of minimal erythema dose (MED)-guided dosing , a patient-specific calibration method that determines the lowest UVB fluence producing visible erythema at 24 hours.

Across the studies reviewed, treatment fluences generally ranged from approximately 200–600 mJ/cm² per session (1–3× MED), (and in some protocols, up to 1,200 mJ/cm² total fluence per session when higher MED multiples are used) . These energy levels are considered higher than typical starting doses in conventional broadband or narrowband UVB phototherapy, reflecting the targeted, lesion-directed dosing inherent in excimer laser protocols .

Prior excimer laser studies (see, e.g. Al-Mutairi N, Al-Haddad A. “Targeted phototherapy using 308 nm Xecl monochromatic excimer laser for psoriasis at difficult to treat sites,” Lasers Med Sci . 2013 Jul;28(4):1119-24. doi: 10.1007/s10103-012-1210-4. Epub 2012 Sep 28. PMID: 23053247) found higher MEDs in certain patient populations , e.g., a mean MED of ~383 mJ/cm² for scalp psoriasis and ~415 mJ/cm² for palmoplantar psoriasis (with ranges up to ~650–950 mJ/cm²), indicating anatomical and individual variability and pointing to a need for high fluence which can only be delivered with energy enabled devices.

STRATA’s latest high-power XTRAC® technology models enable practices to deliver these optimized targeted doses efficiently, supporting short treatment times for patients while maintaining favorable practice economics.

Clinical Significance

The data confirm that MED-based excimer laser dosing consistently produces clinically meaningful and statistically significant PASI reductions .

The publication, authored by established dermatology researchers from Georgetown University and MedStar Washington Hospital Center, highlights continued academic interest in refining targeted UVB strategies within mainstream clinical dermatology.

Conclusion

The February 2026 meta-analysis confirms that 308 nm Excimer Laser therapy, reliably produces significant improvement in plaque psoriasis.

STRATA Skin Sciences remains committed to advancing clinical evidence-based dermatologic therapies that improve outcomes for patients living with chronic inflammatory skin diseases.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC ^® excimer laser, VTRAC ^® lamp systems, and the TheraClear ^® X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. More specific risks and uncertainties are set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com .

Investor Contact:
CORE IR
516-222-2560
[email protected]